Drugs / Triprilimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04475016 | Aug 2020 → May 2022 | penile cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT04421469 | Jun 2020 → Apr 2023 | nasopharyngeal carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04890522 | Jul 2021 → Dec 2023 overdue | metastatic neoplasm, nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triprilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04475016 ↗ |
| Known as | JS001 | “PD-1 antibody JS001” NCT04890522 ↗ |
| Action | Inhibit | “Blocking the immune checkpoint” NCT04890522 ↗ |
| Modality | Monoclonal antibody | “PD-1 antibody JS001” NCT04890522 ↗ |
| Route | Intravenous | “240 mg IV on Day 1” NCT04475016 ↗ |